- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2011-7-15 13:51 编辑
回复 kennyu 的帖子
Replicor had been to China, but I think they cannot find a partner in China. REP 9AC is already tested in human, so it is far ahead than SALP and Mycrudex. Even HBF lists it in their drug watch. So, I believe in Replicor and hope they will further their clinical trials faster.
Non-Nucleoside Antivirals - Interfere with proteins involved in viral reproduction | NOV-205
(BAM 205) | Small Molecule | Novelos
Newton, MA | Approved in Russia | LB80380 (ANA380) | Inhibits viral RNA polymerase | LG Life Sciences,
S. Korea | Phase II | Nitazoxanide (Alinia) | Small Molecule | Romark Labs
Tampa, FL | Phase II Egypt | HAP Compound
Bay 41-4109 | Inhibits viral nucleocapsid | AiCuris, Germany | Phase I | REP 9AC | HBsAg Release Inhibitor | REPLICor Inc.
Montreal, Quebec | Phase I | Nitazoxanide (Alinia) | Small Molecule | Romark Labs
Tampa, FL | Preclinical for H |
|
|